olivLaw · US equity research
Novanta Inc. NOVT
Miscellaneous Electrical Machinery, Equipment & Supplies · SIC 3690 · Vertical: Miscellaneous Electrical Machinery, Equipment & Supplies (SIC 3690)
Novanta Inc. is a global supplier of core technology solutions for medical, life science and advanced industrial original equipment manufacturers. In 2026 the company is accelerating organic growth and widening its medical exposure through the Riverpoint Medical acquisition, which makes its business model more relevant for investors and analysts. Revenue in the second quarter of 2026 reached 265.8 million USD, and annual guidance points to growth above 15 percent.
At the close of 04 Nov 2026, Novanta Inc. (NOVT) stock was 145.23 USD (−1.53% on the day), with market capitalisation 5.5 bn USD, P/E 92.8 on diluted EPS of 1.56 USD over the last 12 months, beta 1.68, 52-week range 99.22–168.75 USD. Latest reported quarter (Q2 2026): revenue of 265.8 m USD (+10.3% YoY), net income of 12.5 m USD (+178.9% YoY), diluted EPS 0.30 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 52.1
- neutral
- Bollinger (20, 2)
- 129.49 – 154.14
- in the upper half of the band · %B 0.64 · band width 17.4%
- SMA 50 / 200
- 142.61 / 142.50
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 1.32 / 0.51
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −3.6% | −1.1% | −2.5 pp | — |
| 3 months | −5.2% | −0.5% | −4.7 pp | — |
| 6 months | +4.6% | +4.4% | +0.2 pp | — |
| Year to date | +22.1% | +12.3% | +9.7 pp | — |
| 1 year | +12.3% | +13.5% | −1.2 pp | −60.2% |
| 3 years | +2.7% | +76.4% | −73.7 pp | −50.2% |
| 5 years | −19.8% | +63.7% | −83.4 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 03 Jul 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 244.4 m | 238.1 m | 233.4 m | 241.0 m | 247.8 m | 258.3 m | 257.7 m | 265.8 m |
| Cost of revenue | 135.2 m | 129.8 m | 129.0 m | 134.3 m | 136.9 m | 145.1 m | 144.1 m | 144.9 m |
| Gross profit | 109.2 m | 108.2 m | 104.4 m | 106.7 m | 110.9 m | 113.3 m | 113.6 m | 120.9 m |
| Research & development | 23.3 m | 25.3 m | 23.2 m | 25.3 m | 24.1 m | 22.9 m | 23.3 m | 24.0 m |
| SG&A | 44.3 m | 43.3 m | 45.6 m | 47.1 m | 51.4 m | 51.6 m | 54.4 m | 60.0 m |
| Operating income | 32.6 m | 26.7 m | 32.4 m | 14.9 m | 21.8 m | 24.8 m | 27.5 m | 18.1 m |
| Depreciation & amortisation | 14.2 m | 14.4 m | 13.6 m | 15.6 m | 15.7 m | 17.1 m | 14.2 m | 14.6 m |
| Pre-tax income | 24.2 m | 20.8 m | 26.4 m | 5.8 m | 15.8 m | 21.7 m | 26.4 m | 15.9 m |
| Income tax | 5.0 m | 4.3 m | 5.2 m | 1.3 m | 5.1 m | 4.2 m | 5.3 m | 3.4 m |
| Net income | 19.2 m | 16.5 m | 21.2 m | 4.5 m | 10.7 m | 17.5 m | 21.1 m | 12.5 m |
| Diluted EPS | 0.53 | 0.46 ≈ | 0.59 | 0.12 | 0.30 | 0.45 ≈ | 0.51 | 0.30 |
| Operating cash flow | 23.0 m ≈ | 61.6 m | 31.7 m | 15.1 m ≈ | 8.5 m ≈ | 8.8 m | 51.6 m | 64.9 m ≈ |
| Capex | 3.6 m ≈ | 2.2 m | 4.3 m | 3.4 m ≈ | 4.3 m ≈ | 3.7 m | 4.1 m | 7.5 m ≈ |
| Share repurchases | — | — | 6.2 m | 0 ≈ | 14.1 m ≈ | 19.1 m | 18.6 m | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 79 percentile of its own 39-quarter history (min 17.1, median 77.5, max 124.7; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 614.3 m | 626.1 m | 590.6 m | 706.8 m | 860.9 m | 881.7 m | 949.2 m | 980.6 m |
| Revenue YoY | +17.8% | +1.9% | −5.7% | +19.7% | +21.8% | +2.4% | +7.7% | +3.3% |
| Net income | 49.1 m | 40.8 m | 44.5 m | 50.3 m | 74.1 m | 72.9 m | 64.1 m | 53.8 m |
| Net income YoY | −18.2% | −17.0% | +9.2% | +13.1% | +47.1% | −1.6% | −12.1% | −16.0% |
| Diluted EPS | 1.43 | 1.15 | 1.25 | 1.41 | 2.06 | 2.02 | 1.77 | 1.47 |
| Diluted EPS YoY | +26.5% | −19.6% | +8.7% | +12.8% | +46.1% | −1.9% | −12.4% | −16.9% |
| net % | 8.0% | 6.5% | 7.5% | 7.1% | 8.6% | 8.3% | 6.8% | 5.5% |
| Free cash flow | 75.0 m | 52.5 m | 129.7 m | 74.6 m | 71.1 m | 100.1 m | 141.4 m | 48.4 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 380.9 m USD
- Financial debt
- 250.8 m USD
- Net debt
- -130.0 m USD
- Equity
- 1.3 bn USD
- Total assets
- 1.8 bn USD
- Debt / equity
- 0.19x
- Current ratio
- 3.69x
- ROE
- 5.2%
- ROA
- 3.4%
- FCF margin
- 4.9%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 590.6 m | 706.8 m | 860.9 m | 881.7 m | 949.2 m | 980.6 m | SEC (XBRL)· 23 Feb 2026verified |
| Cost of revenue | 346.1 m | 406.5 m | 482.4 m | 481.8 m | 527.7 m | 545.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Gross profit | 244.5 m | 300.3 m | 378.5 m | 399.9 m | 421.5 m | 435.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Research & development | 61.0 m | 72.5 m | 85.8 m | 91.7 m | 95.5 m | 95.5 m | SEC (XBRL)· 23 Feb 2026verified |
| SG&A | 109.9 m | 129.2 m | 158.9 m | 164.5 m | 175.9 m | 195.7 m | SEC (XBRL)· 23 Feb 2026verified |
| Operating income | 55.9 m | 64.1 m | 103.1 m | 110.5 m | 110.6 m | 94.0 m | SEC (XBRL)· 23 Feb 2026verified |
| Depreciation & amortisation | 38.3 m | 43.4 m | 53.2 m | 46.6 m | 55.6 m | 61.9 m | SEC (XBRL)· 23 Feb 2026verified |
| EBITDA | 94.2 m ≈ | 107.4 m ≈ | 156.2 m ≈ | 157.1 m ≈ | 166.1 m ≈ | 155.9 m ≈ | SEC (XBRL)· 23 Feb 2026derived |
| Pre-tax income | 48.4 m | 56.2 m | 87.2 m | 83.7 m | 79.1 m | 69.6 m | SEC (XBRL)· 23 Feb 2026verified |
| Income tax | 3.9 m | 5.8 m | 13.1 m | 10.9 m | 15.0 m | 15.8 m | SEC (XBRL)· 23 Feb 2026verified |
| Net income | 44.5 m | 50.3 m | 74.1 m | 72.9 m | 64.1 m | 53.8 m | SEC (XBRL)· 23 Feb 2026verified |
| Diluted EPS | 1.25 | 1.41 | 2.06 | 2.02 | 1.77 | 1.47 | SEC (XBRL)· 23 Feb 2026verified |
| Weighted average diluted shares | 35.7 m | 35.8 m | 35.9 m | 36.0 m | 36.1 m | 36.7 m | SEC (XBRL)· 23 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 125.1 m | 117.4 m | 100.1 m | 105.1 m | 114.0 m | 380.9 m | SEC (XBRL)· 23 Feb 2026verified |
| Receivables | 75.1 m | 115.6 m | 137.7 m | 139.4 m | 151.0 m | 184.9 m | SEC (XBRL)· 23 Feb 2026verified |
| Inventories | 92.7 m | 125.7 m | 168.0 m | 149.4 m | 144.6 m | 188.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Current assets | 304.2 m | 373.8 m | 420.5 m | 415.3 m | 433.6 m | 782.6 m | SEC (XBRL)· 23 Feb 2026verified |
| Property, plant & equipment, net | 78.7 m | 87.4 m | 103.2 m | 109.4 m | 113.1 m | 118.5 m | SEC (XBRL)· 23 Feb 2026verified |
| Goodwill | 286.0 m | 479.5 m | 478.9 m | 484.5 m | 584.1 m | 647.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Intangibles (excl. goodwill) | 148.5 m | 221.0 m | 175.8 m | 145.0 m | 185.8 m | 180.8 m | SEC (XBRL)· 23 Feb 2026verified |
| Total assets | 865.2 m | 1.2 bn | 1.2 bn | 1.2 bn | 1.4 bn | 1.8 bn | SEC (XBRL)· 23 Feb 2026verified |
| Accounts payable | 43.0 m | 68.5 m | 75.2 m | 57.2 m | 76.9 m | 94.9 m | SEC (XBRL)· 23 Feb 2026verified |
| Short-term debt | 5.5 m | 5.1 m | 4.8 m | 5.0 m | 4.7 m | 38.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Long-term debt | 194.9 m | 429.4 m | 430.7 m | 349.4 m | 411.9 m | 212.5 m | SEC (XBRL)· 23 Feb 2026verified |
| Current liabilities | 114.2 m | 183.9 m | 164.5 m | 139.2 m | 167.8 m | 212.4 m | SEC (XBRL)· 23 Feb 2026verified |
| Total liabilities | 388.4 m | 706.6 m | 663.6 m | 552.6 m | 642.8 m | 492.8 m | SEC (XBRL)· 23 Feb 2026verified |
| Equity | 476.8 m | 521.3 m | 577.6 m | 673.5 m | 745.7 m | 1.3 bn | SEC (XBRL)· 23 Feb 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 140.2 m | 94.6 m | 90.8 m | 120.1 m | 158.5 m | 64.1 m | SEC (XBRL)· 23 Feb 2026verified |
| Capex | 10.5 m | 20.0 m | 19.6 m | 20.0 m | 17.2 m | 15.6 m | SEC (XBRL)· 23 Feb 2026verified |
| Free cash flow | 129.7 m ≈ | 74.6 m ≈ | 71.1 m ≈ | 100.1 m ≈ | 141.4 m ≈ | 48.4 m ≈ | SEC (XBRL)· 23 Feb 2026derived |
| Investing cash flow | -13.2 m | -306.7 m | -42.5 m | -19.9 m | -208.2 m | -74.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Financing cash flow | -84.4 m | 204.8 m | -60.2 m | -97.9 m | 56.9 m | 276.3 m | SEC (XBRL)· 23 Feb 2026verified |
| Share repurchases | 5.5 m | — | 10.0 m | — | — | 39.3 m | SEC (XBRL)· 23 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
4 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 45 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 5.5 bn USD
Key indicators
Coverage and freshness
Score by group
- Valuation34
- Returns49
- Quality46
- Balance sheet100
- Growth27
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 35.03 – 69.97 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/Sales35.03 – 68.00 (Mid 54.11)15 companies used · median multiple 1.5x · quartiles 0.8x – 2.0xATKR, CHPT, DFLI, ELVA, ENR, ENS, EOSE, EPOW, GAUZ, MVST, NRGV, SPB, UCAR, ULBI, XPON
- Peers: EV/EBITDA50.50 – 69.97 (Mid 56.78)4 companies used · median multiple 10.8x · quartiles 9.2x – 14.0xATKR, ENS, NVX, SPB
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 45/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| Gross margin · Quality | 44.5% | 11 (on a fixed band) | 11% |
| EBIT margin · Quality | 9.0% | 91 (vs peers) | 9% |
| FCF margin · Quality | 11.1% | 44 (on a fixed band) | 9% |
| Revenue CAGR 3Y · Growth | 4.4% | 18 (on a fixed band) | 17% |
| Revenue growth (YoY) · Growth | 3.3% | 44 (vs peers) | 9% |
| Net debt / EBITDA · Balance sheet | -3.2x | 100 (vs peers) | 6% |
| Current ratio · Balance sheet | 4.6x | 100 (on a fixed band) | 6% |
| EV/Sales · Valuation | 4.9x | 29 (vs peers) | 17% |
| FCF yield · Valuation | 2.1% | 42 (on a fixed band) | 13% |
| Shareholder yield (distributions) · Returns | 0.9% | 49 (on a fixed band) | 4% |
Score groups
- Balance sheet100/100 · 2/2 factors with a value
- Growth27/100 · 2/2 factors with a value
- Quality46/100 · 3/3 factors with a value
- Returns49/100 · 1/1 factors with a value
- Valuation34/100 · 2/2 factors with a value
Memo
NOVANTA INC. (NOVT). Latest full fiscal year: 2025; data up to 2026-07-03.
Figures computed from the financial statements: revenue 980.6 m USD in 2025; YoY growth 3.3%; net margin 6.0%; ROE 5.1%; net debt/EBITDA -3.2x.
The estimated value range is 42.77–68.99 USD per share (median of 2 methods, agreement: same basis (multiples on one peer group, not independent confirmations)); assumptions are illustrative. Against the central value of 55.45 USD, the price of 145.23 USD leaves a potential of -61.8% (value / price − 1) and a margin of safety of -161.9% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 45/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- EBIT margin: 9.0%
- Net debt / EBITDA: -3.2x
- Current ratio: 4.6x
What contradicts it
- Gross margin: 44.5%
- Revenue CAGR 3Y: 4.4%
- EV/Sales: 4.9x
- The price is above the estimated value range
Versus the vertical median
Miscellaneous Electrical Machinery, Equipment & Supplies (SIC 3690) · same industry (4-digit SIC) · compared with 38 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ENSEnerSys | 5.6 bn | 16.7 | 18.4% | 9.3% | +3.7% | +9% / +76% |
| NOVTNovanta Inc. | 5.5 bn | 92.8 | 5.1% | 6.0% | +3.3% | +12% / +3% |
| ATKRAtkore Inc. | 3.2 bn | — | -11.9% | -5.5% | −11.0% | +37% / −24% |
| SPBSpectrum Brands Holdings, Inc. | 2.1 bn | 28.0 | 4.2% | 2.8% | −5.2% | +54% / +32% |
| NVXNOVONIX Ltd | 1.9 bn | — | -62.0% | -1,650.8% | −4.1% | −81% / −88% |
| ENREnergizer Holdings, Inc. | 1.7 bn | 21.3 | 42.2% | 2.7% | +2.3% | +38% / −18% |
| AMPXAmprius Technologies, Inc. | 1.2 bn | — | -36.1% | -33.4% | +202.1% | −25% / +106% |
| EMATEvolution Metals & Technologies Corp. | 1.2 bn | — | — | — | unavailable | unavailable / unavailable |
| EOSEEos Energy Enterprises, Inc. | 779.3 m | — | — | -246.8% | +631.8% | −86% / +95% |
| ENVXEnovix Corporation | 612.3 m | — | -82.2% | -473.9% | +37.9% | −64% / −75% |
| NRGVEnergy Vault Holdings, Inc. | 578.2 m | — | -225.9% | -48.6% | +340.9% | −8% / +38% |
| SLDPSolid Power, Inc. | 515.7 m | — | -20.5% | -1,152.2% | +8.0% | −57% / +60% |
| FLNCFluence Energy, Inc. | 312.1 m | — | -20.7% | -3.1% | −16.1% | −69% / −76% |
| CHPTChargePoint Holdings, Inc. | 306.4 m | — | -1,015.1% | -40.6% | −1.4% | +39% / −69% |
| SESSES AI Corporation | 286.4 m | — | -31.2% | -289.6% | +929.4% | −60% / −63% |
| ULBIEnerSys | 260.3 m | 1.4 | -4.8% | -3.5% | +16.2% | +175% / +109% |
| MVSTMicrovast Holdings, Inc. | 255.7 m | — | 11.4% | 13.9% | +12.6% | −81% / −43% |
| ELVAElectrovaya Inc. | 173.4 m | — | -673.8% | -3.4% | +170.8% | +7% / +94% |
| ELPWElong Power Holding Ltd. | 145.7 m | — | — | -271.3% | +430.7% | −100% / −100% |
| NEOVNeoVolta, Inc. | 134.6 m | — | -101.1% | -161.0% | +58.2% | −44% / +28% |
| GAUZGauzy Ltd. | 127.5 m | — | — | -51.4% | +32.8% | −86% / unavailable |
| BYRNByrna Technologies Inc. | 97.4 m | — | -14.9% | -9.2% | +37.7% | −77% / −29% |
| EPOWE-Power Inc. | 88.8 m | — | — | -35.8% | −28.6% | −88% / −87% |
| BLNKBlink Charging Co. | 65.4 m | — | -79.9% | -52.2% | −18.0% | −66% / −86% |
| STISolidion Technology, Inc. | 37.8 m | — | -1,382.4% | -23,852.8% | unavailable | −59% / −99% |
1- and 3-year price returns: for NOVT from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 89.55 Total return -38% · Per year -38% | 158.33 Total return 9% · Per year 9% | 238.50 Total return 64% · Per year 64% |
| 3 years | 86.80 Total return -40% · Per year -16% | 172.69 Total return 19% · Per year 6% | 285.62 Total return 97% · Per year 25% |
| 5 years | 84.13 Total return -42% · Per year -10% | 188.34 Total return 30% · Per year 5% | 342.06 Total return 136% · Per year 19% |
- Exit P/E± 43.17
- Net margin± 30.22
- Annual revenue growth± 24.82
- Annual dilution± 2.54
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Novanta Inc. is a global supplier of core technology solutions for medical, life science and advanced industrial original equipment manufacturers. In 2026 the company is accelerating organic growth and widening its medical exposure through the Riverpoint Medical acquisition, which makes its business model more relevant for investors and analysts. Revenue in the second quarter of 2026 reached 265.8 million USD, and annual guidance points to growth above 15 percent.
SWOT
Strengths
- The company holds a broad proprietary technology portfolio and deep knowledge of customer applications, which strengthens relationships with OEMs. The mix of medical and industrial markets reduces dependence on a single economic cycle.
- Products designed into customer systems face high barriers to replacement over the life cycle, especially in medical, which supports recurring revenue.
- Organic growth accelerated in 2026 and a solid backlog gives some visibility into future demand.
Weaknesses
- Operating income declined in fiscal 2025 compared with the prior year, due to higher selling and administrative costs and restructuring and acquisition expenses.
- A significant part of components and subassemblies comes from a limited number of suppliers, some of them single sources, creating supply risk.
- The company carries debt and credit agreements with financial covenants, and integrating Riverpoint may require close attention to compliance.
Opportunities
- Expansion in minimally invasive and robotic surgery could raise the medical share and the higher-margin recurring consumables business.
- Industrial applications such as robotics, additive manufacturing and automation could become long-term growth drivers.
- Regionalising production and building centres of excellence could lower costs and ease access to regulated markets.
Threats
- Tariffs, retaliatory measures and changing trade policy could raise costs and weigh on demand in certain regions.
- Cycles in microelectronics and capital equipment can produce sudden demand declines that are hard to anticipate.
- Competitors that innovate faster, including through artificial intelligence based technologies, could make existing products less competitive.
Risks
- Dependence on large OEM customershigh
A few OEM customers in medical account for significant portions of revenue, and losing or reducing orders from them could affect results.
- Exposure to tariffs and trade policyhigh
Changes in tariffs and trade agreements could raise production costs and reduce the competitiveness of products made in certain locations.
- Cyclicality of industrial marketsmedium
Demand in microelectronics and industrial equipment is cyclical, which could create quarter-to-quarter volatility in revenue and profit.
- Integration of acquisitionsmedium
Integrating Riverpoint Medical and other acquisitions could prove difficult, and the performance of an acquired business can be harder to forecast.
- Cybersecurity threatslow
Cyberattacks and security incidents could disrupt IT systems and expose confidential data, with remediation costs and liability.
Investment thesis
What would need to be true (bull case)
- If the acceleration in organic growth seen in the second quarter of 2026 is sustained, the company could reach its annual revenue guidance.
- The Riverpoint Medical acquisition could increase the share of recurring consumables and could improve margins and profitability.
- Products integrated into OEM systems could generate stable revenue over long product life cycles.
What would break the thesis
- If tariffs and trade tensions persist, production costs could rise faster than selling prices.
- Cyclical downturns in microelectronics or capital equipment could abruptly reduce demand for the automation segment.
- If integration of acquisitions or the performance of Riverpoint falls short of forecasts, profitability could come in below expectations.
What to watch
- Delivery of third-quarter 2026 revenue guidance (300 to 304 million USD)Q3 2026
- Development of organic growth and backlog after the Riverpoint acquisitionQ4 2026
- Achievement of full-year revenue and Adjusted EBITDA guidance2026
- Trend in customer concentration and the medical share of revenuenext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Novanta Inc. and its subsidiaries supply proprietary components and subsystems to original equipment manufacturers (OEMs) in the medical and advanced industrial markets. Over time the company has shifted from a focus on the semiconductor industry to one centred on medical and automation applications. Sales are made mainly through a direct technical sales force and partly through distributors.
The strategy aims to raise the share of medical sales through products for minimally invasive and robotic surgery, through complementary acquisitions, and through growth in high-growth industrial applications such as robotics, laser additive manufacturing and automation. Novanta also emphasises operational efficiency, with lean manufacturing and regionalised plants, which could support margins over the long term.
Customers are largely OEMs that integrate Novanta products into their systems, and once a product is designed in, switching suppliers is difficult over its life cycle, especially in medical. The company reports two segments: Automation Enabling Technologies and Medical Solutions.
Market context
The company operates mainly in two end markets: medical, which accounted for about 53 percent of revenue in 2025, and advanced industrial, at about 47 percent. Medical demand depends on hospital capital budgets, surgical procedure volumes and regulation, while industrial demand follows investment cycles and PMI indicators. More than 47 percent of revenue came from outside the U.S. in 2025.
Consolidated backlog was about 481.2 million USD at the end of fiscal 2025, up from the prior year. The company notes, however, that backlog is not a complete indicator of future revenue because customers can reschedule orders. Guidance for 2026 includes the contribution of the Riverpoint Medical acquisition.
Trends
- Acceleration of organic growthtailwind
In the second quarter of 2026 organic revenue growth was 9.3 percent, the strongest organic quarter since the first quarter of 2023, and management sees momentum building into the second half. If bookings and backlog hold, this momentum could support the annual guidance.
- Expansion in minimally invasive surgerytailwind
The Riverpoint Medical acquisition increases recurring medical consumables and raises medical exposure to about 60 percent of revenue, according to management. The medical strategy is supported by demand for robotic and minimally invasive surgery.
- Tariffs and trade policy changesheadwind
New tariffs, retaliatory measures and renegotiated trade agreements have affected production costs and the market for the company's products, and management says uncertainty persists. These could compress margins or slow demand in some regions.
- Cyclicality of the microelectronics industrymixed
Some advanced industrial sub-sectors, such as microelectronics and capital equipment, are cyclical and have experienced oversupply in the past. Demand downturns can affect the Automation Enabling Technologies segment directly, and their timing is hard to predict.
Competitive position
Novanta operates in markets with strong competition, ranging from large domestic and foreign organisations offering broad product lines to small firms specialised in niche applications. Success depends on technological performance, price-for-performance ratios, quality, application expertise and customer relationships.
According to the filing, the company's advantage lies in the breadth of its technologies and its deep application knowledge, which allow it to design products for OEMs. Once a product is integrated into a system, barriers to changing supplier are significant, especially in medical.
- Large domestic and foreign organisations with broad product lines
The source describes competitors only generically, without naming them, and their size and profile vary.
- Small firms specialised in niche applications
These companies compete on highly specialised products and are not identified in the documents provided.
- Suppliers of components for robotics and automation
The sources mention competition in the automation segment but do not name specific companies.
- Suppliers of minimally invasive medical equipment
Competition in medical is described generically, and the identity of competitors does not appear in the documents.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Novanta’s (NOVT) Second Quarter Shows Profits Outrunning SalesYahoo Finance — News · 04 Sept 2026 · EN
The latest news item in our archive is from 04 Sept 2026; the newest SEC filing is from 02 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report (amendment)02 Oct 2026Financial statements and exhibits
- Quarterly report05 Aug 2026
- Current report05 Aug 2026Results of operations · Financial statements and exhibits
- Current report27 Jul 2026Acquisition or disposition of assets · Creation of a direct financial obligation · Regulation FD disclosure · Financial statements and exhibits
- Current report09 Jun 2026Material agreement · Item 3.02 · Other events · Financial statements and exhibits
- Current report09 Jun 2026Material agreement · Regulation FD disclosure · Financial statements and exhibits
- Current report29 May 2026Shareholder vote
- Current report15 May 2026Material agreement · Creation of a direct financial obligation · Financial statements and exhibits
- Quarterly report11 May 2026
- Current report11 May 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Novanta Inc. · 23 Feb 2026
- [2] Form 10-Q, quarter ended 2026-07-03 · SEC / Novanta Inc. · 05 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Novanta Inc. · 05 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.